- In March 2024, Lonza entered into an agreement with Roche to acquire Genentech's biologics manufacturing facility in California for over USD 1 billion. This acquisition is poised to significantly bolster Lonza’s biologics manufacturing capabilities, positioning the site as one of the largest in the world. This strategic move by Lonza is contributes to the global empty capsules market, as the demand for biologics, particularly in the pharmaceutical and nutraceutical sectors, continues to rise
- In March 2023, VANTAGE NUTRITION, a subsidiary of ACG, acquired ComboCap, Inc. in the United States and BioCap in South Africa, with the strategic aim of expanding its technological capabilities and global presence, particularly in North America. This acquisition reflects the growing demand for advanced capsule technologies, particularly in North America and emerging markets. By integrating ComboCap and BioCap’s expertise, VANTAGE NUTRITION is well-positioned to meet the increasing need for high-quality capsule solutions across various pharmaceutical and nutraceutical sector
- In January 2022, Xi'an Le-Nutra Ingredients Inc. successfully shipped 8.0 million HPMC capsules to Latvia, Europe, without the inclusion of titanium dioxide (TiO2). This move underscores the company's commitment to addressing the growing demand for clean-label, TiO2-free capsules in the region. This development highlights the increasing consumer and regulatory preference for natural, clean-label products
- In July 2020, QUALICAPS Group, previously a part of Mitsubishi Chemical Holdings Corporation (MCHC), transitioned to Mitsubishi Chemical Corporation (MCC). This strategic shift enables QUALICAPS to capitalize on MCC’s extensive network, thereby enhancing its capacity to expand and strengthen its position in the global capsule market. This transition highlights QUALICAPS’ strategic efforts to leverage MCC’s resources and global reach. By tapping into this expanded network, QUALICAPS is well-positioned to meet the growing demand for high-quality capsules across various pharmaceutical and nutraceutical sector
- In June 2020, Lonza launched DBcaps, a double-blinded HPMC capsule specifically designed for clinical trials. This innovative product aims to address the challenges associated with clinical testing by providing an effective solution for maintaining trial integrity and ensuring unbiased results. This development underscores the increasing demand for specialized, high-quality capsules in clinical research
